Astal Laboratories Ltd signs LOI with Immuna Therapeutics GmbH

Astal Laboratories Limited has signed a Letter of Intent (LOI) with Switzerland-based Immuna Therapeutics GmbH for the exclusive India rights to next-generation CART cell therapies, including TriCAR-T platforms.

The proposed collaboration covers technology transfer, localization of manufacturing, clinical development, and commercialization in India. The initiative supports Company's long-term strategy to expand into highvalue advanced therapies and cell and gene therapy platforms.

Astal estimates the collaboration will generate incremental revenue of approximately ₹300 crore upon implementation, driven by rising demand for advanced oncology treatments and improved access through localized manufacturing.

The partnership positions the Company at the forefront of next-generation immuno-oncology in India while creating a scalable platform for future cell therapy programs.

Shares of Astal Laboratories LTD. was last trading in BSE at Rs. 87.97 as compared to the previous close of Rs. 88.84. The total number of shares traded during the day was 10170 in over 156 trades.

The stock hit an intraday high of Rs. 89.90 and intraday low of 84.50. The net turnover during the day was Rs. 885688.00.

Source : Equity Bulls

Keywords

AstalLaboratories INE307N01014 LOI ImmunaTherapeuticsGmbH